SNAPS Breast Cancer Patient Study Breast Cancer Patients
Subtraction Normalized Aggregated Phagocytic Signal in Peripheral Blood of Breast Cancer Patients (SNAPS - Clinical Trial) A NextGen RNASeq Feasibility Study of a Blood-based Model for Early Cancer Detection and Surveillance
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * Patients \> 18 yrs of age. * Patients diagnosed with stage I-IV breast cancer, who have not begun definitive therapy. * Patients undergoing screening mammograms for breast cancer. Exclusion Criteria: * Patients with a history of a different cancer within the previous 3 years (except non melanoma skin cancer). * Any prior treatment (surgery, chemo, hormonal, radiation, biologics, etc.) for current cancer. * Any biopsy which resulted in the entire tumor tissue being removed. * History of previous breast cancer. * Patients unable to provide informed consent. * Patients with an abnormal screening mammogram. * Patients whose hormone receptor and/or HER2 status are not available.
Study sites (1)
NC
- Duke University · Durham, NC 27710Amanda Nash · Study contact · 855-855-6484Amanda Nash · Study contactShelley Hwang, MD · Principal investigatorMore trials in Durham